Skip to content
value.today

Elixirgen Therapeutics, Inc.

🇺🇸 Baltimore, Maryland, USABiotechnologyFounded 2017

Formerly ELIXIRGEN THERAPEUTICS, LLC

Total raised
$29 M
6 rounds on record
Latest round
$4 M
Oct 2025
First round on record
Jun 2018
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Elixirgen Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$4 MNo. 6$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 6, Oct 2025

Investors in this round

1 investor had bought by the notice of Nov 13, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro Ko · Executive Officer, Director
  • Hiroaki Kobayashi · Director
  • Jeffrey Cleland · Director
  • Minoru Ko · Director
  • Shauna Callahan · Director
  • Thomas White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Nov 13, 2025. Read the notice at the SEC.

debt, optionsSEC
Mar 2025$4 MNo. 5$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 5, Mar 2025

Investors in this round

2 investors had bought by the notice of Apr 9, 2025: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro Ko · Executive Officer, Director
  • Hiroaki Kobayashi · Director
  • Jeffrey Cleland · Director
  • Minoru Ko · Director
  • Shauna Callahan · Director
  • Thomas White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Apr 9, 2025. Read the notice at the SEC.

debt, optionsSEC
Nov 2023$7 MNo. 4$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 4, Nov 2023

Investors in this round

1 investor had bought by the notice of Dec 1, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro C Ko · Executive Officer, Director
  • Hiroaki C Kobayashi · Director
  • Jeffrey K. Cleland · Director
  • Minoru S.H. Ko · Director
  • Shauna K. Callahan · Director
  • Thomas K. White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This pertains to the issuance of Series A-3 Preferred Units, including the conversion of convertible securities”

Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Dec 1, 2023. Read the notice at the SEC.

equitySEC
Feb 2021$4 MNo. 3$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 3, Feb 2021

Investors in this round

2 investors had bought by the notice of Feb 18, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro Ko · Executive Officer, Director
  • Hiroaki Kobayashi · Director
  • Minoru Ko · Director
  • Naonori Kurokawa · Director
  • Shauna Callahan · Director
  • Thomas White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akihiro Ko, CEO / Director. Source: SEC Form D, newest notice filed Feb 18, 2021. Read the notice at the SEC.

equitySEC
Nov 2019$6 MNo. 2$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 2, Nov 2019

Investors in this round

3 investors had bought by the notice of Aug 17, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro Ko · Executive Officer, Director
  • Maiko Katadae · Director
  • Minoru Ko · Director
  • Naonori Kurokawa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akihiro Ko, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2020. Read the notice at the SEC.

equitySEC
Jun 2018$4 MNo. 1$2 to $10 million

Elixirgen Therapeutics, Inc.: Raise no. 1, Jun 2018

Investors in this round

1 investor had bought by the notice of Jun 25, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akihiro Ko · Executive Officer, Director
  • Minoru S.H. Ko · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Akihiro Ko, Chief executive officer. Source: SEC Form D, newest notice filed Jun 25, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Elixirgen Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2025

That is all the official record says: Elixirgen Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Elixirgen Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 3 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elixirgen Therapeutics, Inc.
NameRoleNamed in
Akihiro KoExecutive officerNov 2025
Akihiro C KoExecutive officerDec 2023
Akihiro KoDirectorNov 2025
Hiroaki KobayashiDirectorNov 2025
Jeffrey ClelandDirectorNov 2025
Minoru KoDirectorNov 2025
Shauna CallahanDirectorNov 2025
Thomas WhiteDirectorNov 2025
Akihiro C KoDirectorDec 2023
Hiroaki C KobayashiDirectorDec 2023
Jeffrey K. ClelandDirectorDec 2023
Minoru S.H. KoDirectorDec 2023
Shauna K. CallahanDirectorDec 2023
Thomas K. WhiteDirectorDec 2023
Naonori KurokawaDirectorFeb 2021
Maiko KatadaeDirectorAug 2020